Sulfadiazine analogs: anti-Toxoplasma in vitro study of sulfonamide triazoles.

Sulfadiazine / pharmacology Toxoplasma Sulfanilamide Sulfonamides Triazoles
1,2,3-triazoles Click chemistry In vitro study SEM TEM Toxoplasma gondii

Journal

Parasitology research
ISSN: 1432-1955
Titre abrégé: Parasitol Res
Pays: Germany
ID NLM: 8703571

Informations de publication

Date de publication:
Oct 2023
Historique:
received: 27 05 2023
accepted: 03 08 2023
medline: 12 9 2023
pubmed: 23 8 2023
entrez: 23 8 2023
Statut: ppublish

Résumé

Toxoplasmosis is an infection that prevails all over the world and is caused by the obligate intracellular protozoan parasite Toxoplasma gondii (T. gondii). Promising novel compounds for the treatment of T. gondii are introduced in the current investigation. In order to test their in vitro potency against T. gondii tachyzoites, six 1,2,3-triazoles-based sulfonamide scaffolds with terminal NH

Identifiants

DOI: 10.1007/s00436-023-07936-x PMID: 37610452 PMC: PMC10495491
pubmed: 37610452
doi: 10.1007/s00436-023-07936-x
pii: 10.1007/s00436-023-07936-x
pmc: PMC10495491
doi:

Substances chimiques

Sulfadiazine 0N7609K889
Sulfanilamide 21240MF57M
Sulfonamides 0
Triazoles 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2353-2365

Informations de copyright

© 2023. The Author(s).

Références

Aikawa M, Komata Y, Asai T, Midorikawa O (1977) Transmission and scanning electron microscopy of host cell entry by Toxoplasma gondii. Am J Pathol 87(2):285
pubmed: 851168 pmcid: 2032037
Aljohani FS et al (2022) Synthesis, characterization and nanoformulation of novel sulfonamide-1, 2, 3-triazole molecular conjugates as potent antiparasitic agents. Int J Mol Sci 23(8):4241
pubmed: 35457059 pmcid: 9025934 doi: 10.3390/ijms23084241
Al-Malki ES (2021) Toxoplasmosis: stages of the protozoan life cycle and risk assessment in humans and animals for an enhanced awareness and an improved socio-economic status. Saudi J Biol Sci 28(1):962–969
doi: 10.1016/j.sjbs.2020.11.007
Almeida-Souza F et al (2020) 1, 4-Disubstituted-1, 2, 3-Triazole compounds induce ultrastructural alterations in leishmania amazonensis promastigote: an in vitro antileishmanial and in silico pharmacokinetic study. Int J Mol Sci 21(18):6839
pubmed: 32961842 pmcid: 7555349 doi: 10.3390/ijms21186839
Anderson AC (2005) Targeting DHFR in parasitic protozoa. Drug Discov Today 10(2):121–128
pubmed: 15718161 doi: 10.1016/S1359-6446(04)03308-2
Bérubé G (2016) An overview of molecular hybrids in drug discovery. Expert Opin Drug Discovery 11(3):281–305
doi: 10.1517/17460441.2016.1135125
Boyle JP, Saeij JP, Coller SP, Boothroyd JC (2006) Polymorphic secreted kinases are key virulence factors in toxoplasmosis. Am J Trop Med Hyg 314(5806):1780–1783
Carvalho C, De Melo E (2010a) Anti-parasitic action and elimination of intracellular Toxoplasma gondii in the presence of novel thiosemicarbazone and its 4-thiazolidinone derivatives. Braz J Med Biol Res 43(2):139–149
pubmed: 19893994 doi: 10.1590/S0100-879X2009005000038
Celik F, Unver Y, Barut B, Ozel A, Sancak K (2018) Synthesis, characterization and biological activities of new symmetric bis-1, 2, 3-triazoles with click chemistry. Med Chem 14(3):230–241
pubmed: 29165092 doi: 10.2174/1573406413666171120165226
Chen Y et al (2018) Identification of novel and selective non-peptide inhibitors targeting the polo-box domain of polo-like kinase 1. Bioorg Chem 81:278–288
pubmed: 30170276 doi: 10.1016/j.bioorg.2018.08.030
Choi W-Y et al (1997) Foodborne outbreaks of human toxoplasmosis. J Infect Dis 175(5):1280–1282
pubmed: 9129105 doi: 10.1086/593702
Chou T-C (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58(3):621–681
pubmed: 16968952 doi: 10.1124/pr.58.3.10
Chou T-C, Talaly P (1977) A simple generalized equation for the analysis of multiple inhibitions of Michaelis-Menten kinetic systems. J Biol Chem 252(18):6438–6442
pubmed: 893418 doi: 10.1016/S0021-9258(17)39978-7
Chulay JD, Watkins WM, Sixsmith DG (1984) Synergistic antimalarial activity of pyrimethamine and sulfadoxine against Plasmodium falciparum in vitro. Am J Trop Med Hyg 33(3):325–330
pubmed: 6375404 doi: 10.4269/ajtmh.1984.33.325
Conseil V, Soete M, Dubremetz J (1999) Serine protease inhibitors block invasion of host cells by Toxoplasma gondii. Antimicrob Agents Chemother 43(6):1358–1361
pubmed: 10348752 pmcid: 89278 doi: 10.1128/AAC.43.6.1358
Craik DJ, Fairlie DP, Liras S, Price D (2013) The future of peptide-based drugs. Chem Biol Drug Des 81(1):136–147
pubmed: 23253135 doi: 10.1111/cbdd.12055
de Souza W, Attias M (2018) New advances in scanning microscopy and its application to study parasitic protozoa. Exp Parasitol 190:10–33
pubmed: 29702111 doi: 10.1016/j.exppara.2018.04.018
Derouin F, Chastang C (1989) In vitro effects of folate inhibitors on Toxoplasma gondii. Antimicrob Agents Chemother 33(10):1753–1759
pubmed: 2531568 pmcid: 172750 doi: 10.1128/AAC.33.10.1753
Diab M, El-Bahy M (2008) Toxoplasma gondii: virulence of tachyzoites in serum free media at different temperatures. Exp Parasitol 118(1):75–79
pubmed: 17904554 doi: 10.1016/j.exppara.2007.06.009
Djurković-Djaković O, Nikolić A, Bobić B, Klun I, Aleksić A (2005) Stage conversion of Toxoplasma gondii RH parasites in mice by treatment with atovaquone and pyrrolidine dithiocarbamate. Microbes Infect 7(1):49–54
pubmed: 15716077 doi: 10.1016/j.micinf.2004.09.016
Dubey JP (2016) Toxoplasmosis of animals and humans. CRC press
doi: 10.1201/9781420092370
Eaton MS, Weiss LM, Kim K (2006) Cyclic nucleotide kinases and tachyzoite–bradyzoite transition in Toxoplasma gondii. Int J Parasitol 36(1):107–114
pubmed: 16216248 doi: 10.1016/j.ijpara.2005.08.014
Elkerdany ED, Elnassery SM, Arafa FM, Zaki SA, Mady RF (2020) In vitro effect of a novel protease inhibitor cocktail on Toxoplasma gondii tachyzoites. Exp Parasitol 219:108010
pubmed: 33007297 doi: 10.1016/j.exppara.2020.108010
El-Tombary AA, Ismail KA, Aboulwafa OM, Omar A-MM, El-Azzouni MZ, El-Mansoury ST (1999) Novel triazolo [4, 3-a] quinazolinone and bis-triazolo [4, 3-a: 4, 3′-c] quinazolines: synthesis and antitoxoplasmosis effect. Il Farmaco 54(7):486–495
pubmed: 10486917 doi: 10.1016/S0014-827X(99)00038-5
Eng R, Padberg F, Smith S, Tan E, Cherubin C (1991) Bactericidal effects of antibiotics on slowly growing and nongrowing bacteria. Antimicrob Agents Chemother 35(9):1824–1828
pubmed: 1952852 pmcid: 245275 doi: 10.1128/AAC.35.9.1824
Ertl P, Rohde B, Selzer P (2000) Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. J Med Chem 43(20):3714–3717
pubmed: 11020286 doi: 10.1021/jm000942e
Galal L, Hamidović A, Dardé ML, Mercier M (2019) Diversity of Toxoplasma gondii strains at the global level and its determinants. Food Waterborne Parasitol 15:e00052
pubmed: 32095622 pmcid: 7033991 doi: 10.1016/j.fawpar.2019.e00052
Guo H, Gao Y, N'Da DD, Xuan X (2021) In vitro anti-Toxoplasma gondii efficacy of synthesised benzyltriazole derivatives. Onderstepoort J Vet Res 88(1):1–8
doi: 10.4102/ojvr.v88i1.1898
Hammouda N, El-Mansoury S, El-Azzouni M (1992) Toxoplasma gondii: scanning electron microscopic study before and after treatment. J Trop Med 2:77–83
Hermes G et al (2008) Neurological and behavioral abnormalities, ventricular dilatation, altered cellular functions, inflammation, and neuronal injury in brains of mice due to common, persistent, parasitic infection. J Neuroinflammation 5(1):1–37
doi: 10.1186/1742-2094-5-48
Hernandez AV et al (2017) A systematic review and meta-analysis of the relative efficacy and safety of treatment regimens for HIV-associated cerebral toxoplasmosis: is trimethoprim-sulfamethoxazole a real option? HIV Med 18(2):115–124
pubmed: 27353303 doi: 10.1111/hiv.12402
Hopper AT et al (2019) Discovery of selective Toxoplasma gondii dihydrofolate reductase inhibitors for the treatment of toxoplasmosis. J Med Chem 62(3):1562–1576
pubmed: 30624926 pmcid: 6571122 doi: 10.1021/acs.jmedchem.8b01754
Howe DK, Sibley LD (1995) Toxoplasma gondii comprises three clonal lineages: correlation of parasite genotype with human disease. J Infect Dis 172(6):1561–1566
pubmed: 7594717 doi: 10.1093/infdis/172.6.1561
Huisgen R (1963) 1, 3-dipolar cycloadditions. Past and future. Angew Chem Int Ed Engl 2(10):565–598
doi: 10.1002/anie.196305651
Jeliński T, Przybyłek M, Cysewski P (2019) Solubility advantage of sulfanilamide and sulfacetamide in natural deep eutectic systems: experimental and theoretical investigations. Drug Dev Ind Pharm 45(7):1120–1129
pubmed: 30883240 doi: 10.1080/03639045.2019.1597104
Khosravi M, Mohammad Rahimi H, Doroud D, Mirsamadi ES, Mirjalali H, Zali MR (2020) In vitro evaluation of mannosylated paromomycin-loaded solid lipid nanoparticles on acute toxoplasmosis. Front Cell Infect Microbiol 10:33
pubmed: 32117807 pmcid: 7031658 doi: 10.3389/fcimb.2020.00033
Kongsaengdao S, Samintarapanya K, Oranratnachai K, Prapakarn W, Apichartpiyakul C (2008) Randomized controlled trial of pyrimethamine plus sulfadiazine versus trimethoprim plus sulfamethoxazole for treatment of toxoplasmic encephalitis in AIDS patients. J Int Assoc Physicians AIDS Care 7(1):11–16
doi: 10.1177/1545109707301244
Kumar S, Khokra SL, Yadav A (2021) Triazole analogues as potential pharmacological agents: a brief review. Future J Pharm Sci 7(1):1–22
Kumar S, Prahalathan P, Saravanakumar M, Raja B (2014) Vanillic acid prevents the deregulation of lipid metabolism, endothelin 1 and up regulation of endothelial nitric oxide synthase in nitric oxide deficient hypertensive rats. Eur J Pharmacol 743:117–125
pubmed: 25239071 doi: 10.1016/j.ejphar.2014.09.010
Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (2012) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 64:4–17
doi: 10.1016/j.addr.2012.09.019
McGettigan BD, Hew M, Phillips E, McLean-Tooke A (2012) Sulphadiazine-induced renal stones in a 63-year-old HIV-infected man treated for toxoplasmosis. Case Rep Dermatol 2012:bcr2012006638
Molina DA et al (2021) In vitro evaluation of new 4-thiazolidinones on invasion and growth of Toxoplasma gondii. Int J Parasitol Drugs Drug Resist 16:129–139. https://doi.org/10.1016/j.ijpddr.2021.05.004
doi: 10.1016/j.ijpddr.2021.05.004 pubmed: 34102589 pmcid: 8187164
Montazeri M et al (2020) Anti-Toxoplasma activities of the hydroalcoholic extract of some brassicaceae species. Adv Biomed Res 9:5
pubmed: 32055539 pmcid: 7003551 doi: 10.4103/abr.abr_206_19
Ozgonul C, Besirli CG (2017) Recent developments in the diagnosis and treatment of ocular toxoplasmosis. Ophthalmic Res 57(1):1–12
pubmed: 27723657 doi: 10.1159/000449169
Paredes-Santos T, Martins-Duarte E, Vitor R, De Souza W, Attias M, Vommaro R (2013) Spontaneous cystogenesis in vitro of a Brazilian strain of Toxoplasma gondii. Parasitol Int 62(2):181–188
pubmed: 23269201 doi: 10.1016/j.parint.2012.12.003
Park Y-H, Han J-H, Nam H-W (2011) Clinical features of ocular toxoplasmosis in Korean patients. Korean J Parasitol 49(2):167
pubmed: 21738273 pmcid: 3121074 doi: 10.3347/kjp.2011.49.2.167
Pink R, Hudson A, Mouriès M-A, Bendig M (2005) Opportunities and challenges in antiparasitic drug discovery. Nat Rev Drug Discov 4(9):727–740
pubmed: 16138106 doi: 10.1038/nrd1824
Portes JA et al (2018) A new iron (III) complex-containing sulfadiazine inhibits the proliferation and induces cystogenesis of Toxoplasma gondii. Parasitol Res 117(9):2795–2805
pubmed: 29934691 doi: 10.1007/s00436-018-5967-7
Ryu B-Y, Emrick T (2011) Bisphenol-1, 2, 3-triazole (BPT) epoxies and cyanate esters: synthesis and self-catalyzed curing. Macromolecules 44(14):5693–5700
doi: 10.1021/ma200767j
Saeedi M et al (2019) Design and synthesis of novel quinazolinone-1, 2, 3-triazole hybrids as new anti-diabetic agents: in vitro α-glucosidase inhibition, kinetic, and docking study. Bioorg Chem 83:161–169
pubmed: 30366316 doi: 10.1016/j.bioorg.2018.10.023
Sahu A, Sahu P, Agrawal R (2020) A recent review on drug modification using 1, 2, 3-triazole. Curr Chem Biol 14(2):71–87
doi: 10.2174/2212796814999200807214519
Said MA et al (2021) New 1, 2, 3-triazole scaffold schiff bases as potential anti-COVID-19: design, synthesis, DFT-molecular docking, and cytotoxicity aspects. Vaccines 9(9):1012
pubmed: 34579249 pmcid: 8472185 doi: 10.3390/vaccines9091012
Sanchez SG, Besteiro S (2021) The pathogenicity and virulence of Toxoplasma gondii. Virulence 12(1):3095–3114
pubmed: 34895084 pmcid: 8667916 doi: 10.1080/21505594.2021.2012346
Saraf P, Shwab EK, Dubey JP, Su C (2017) On the determination of Toxoplasma gondii virulence in mice. Exp Parasitol 174:25–30
pubmed: 28153801 doi: 10.1016/j.exppara.2017.01.009
Shaw MK, Roos DS, Tilney LG (2002) Cysteine and serine protease inhibitors block intracellular development and disrupt the secretory pathway of Toxoplasma gondii. Microbes Infect 4(2):119–132
pubmed: 11880042 doi: 10.1016/S1286-4579(01)01520-9
Smith CL, Powell KR (2000) Review of the sulfonamides and trimethoprim. Pediatr Rev 21(11):368–371
pubmed: 11077020 doi: 10.1542/pir.21.11.368
Thebault A, Kooh P, Cadavez V, Gonzales-Barron U, Villena I (2021) Risk factors for sporadic toxoplasmosis: a systematic review and meta-analysis. Microbial Risk Analysis 17:100133
doi: 10.1016/j.mran.2020.100133
Viegas-Junior C, Danuello A, da Silva BV, Barreiro EJ, Fraga CAM (2007) Molecular hybridization: a useful tool in the design of new drug prototypes. Curr Med Chem 14(17):1829–1852
pubmed: 17627520 doi: 10.2174/092986707781058805
Wei H-X, Wei S-S, Lindsay DS, Peng H-J (2015) A systematic review and meta-analysis of the efficacy of anti-Toxoplasma gondii medicines in humans. PloS One 10(9):e0138204
pubmed: 26394212 pmcid: 4578932 doi: 10.1371/journal.pone.0138204
Winey M, Meehl JB, O'Toole ET, Giddings TH Jr (2014) Conventional transmission electron microscopy. Mol Biol Cell 25(3):319–323
pubmed: 24482357 pmcid: 3907272 doi: 10.1091/mbc.e12-12-0863
Wong S-Y, Remington JS (1993) Biology of Toxoplasma gondii. AIDS (London, England) 7(3):299–316
pubmed: 8471191 doi: 10.1097/00002030-199303000-00001
Yamini L, Vijjulatha M (2008) Inhibitors of human dihydrofolate reductase: a computational design and docking studies using glide. E-Journal of Chemistry 5(2):263–270
doi: 10.1155/2008/401738
Zhang R-H, Jin R, Deng H, Shen Q-K, Quan Z-S, Jin C-M (2021) Evaluation of the anti-Toxoplasma gondii activity of hederagenin in vitro and in vivo. Korean J Parasitol 59(3):297
pubmed: 34218602 pmcid: 8255499 doi: 10.3347/kjp.2021.59.3.297
Zhang S et al (2017) Triazole derivatives and their anti-tubercular activity. Eur J Med Chem 138:501–513
pubmed: 28692915 doi: 10.1016/j.ejmech.2017.06.051

Auteurs

Fadwa M Arafa (FM)

Department of Medical Parasitology, Faculty of Medicine, Alexandria University, Alexandria, 21577, Egypt. f_arafa10@alexmed.edu.eg.

Doaa Hassan Osman (DH)

Department of Parasitology, Medical Research Institute, Alexandria University, Alexandria, 21561, Egypt.

Mona Mohamed Tolba (MM)

Department of Parasitology, Medical Research Institute, Alexandria University, Alexandria, 21561, Egypt.

Nadjet Rezki (N)

Department of Chemistry, College of Science, Taibah University, Al-Madinah Al-Munawarah, 30002, Saudi Arabia.

Mohamed R Aouad (MR)

Department of Chemistry, College of Science, Taibah University, Al-Madinah Al-Munawarah, 30002, Saudi Arabia.

Mohamed Hagar (M)

Department of Chemistry, Faculty of Science, Alexandria University, Alexandria, 21321, Egypt.

Mervat Osman (M)

Department of Parasitology, Medical Research Institute, Alexandria University, Alexandria, 21561, Egypt.

Heba Said (H)

Department of Parasitology, Medical Research Institute, Alexandria University, Alexandria, 21561, Egypt.

Articles similaires

Overcoming multi-drug resistance in SCLC: a synergistic approach with venetoclax and hydroxychloroquine targeting the lncRNA LYPLAL1-DT/BCL2/BECN1 pathway.

Shuxin Li, Jianyi Lv, Zhihui Li et al.
1.00
Humans Small Cell Lung Carcinoma RNA, Long Noncoding Sulfonamides Animals

Single-cell landscape of innate and acquired drug resistance in acute myeloid leukemia.

Rebekka Wegmann, Ximena Bonilla, Ruben Casanova et al.
1.00
Humans Leukemia, Myeloid, Acute Drug Resistance, Neoplasm Single-Cell Analysis Sulfonamides

Trend in serological and molecular diagnostic methods for Toxoplasma gondii infection.

Min-Ju Kim, Soeun J Park, Hyunwoo Park
1.00
Humans Toxoplasmosis Toxoplasma Serologic Tests Molecular Diagnostic Techniques

Treatment with oclacitinib, a Janus kinase inhibitor, down-regulates and up-regulates CD25 and Foxp3 expression, respectively, in peripheral blood T cells of dogs with atopic dermatitis.

Agnieszka Jasiecka-Mikołajczyk, Piotr Socha
1.00
Animals Dermatitis, Atopic Dogs Pyrimidines Forkhead Transcription Factors

Classifications MeSH

Recherchemedicale.com › Composés chimiques organiques › Composés du soufre › Sulfones › Sulfonamides › Sulfamides › Sulfadiazine › Sulfadiazine analogs: anti-Toxoplasma in vitro...
Recherchemedicale.com › Eucaryotes › Alveolata › Apicomplexa › Coccidia › Eimeriida › Sarcocystidae › Toxoplasma › Sulfadiazine analogs: anti-Toxoplasma in vitro...
Recherchemedicale.com › Composés chimiques organiques › Composés du soufre › Sulfones › Sulfonamides › Sulfamides › Sulfanilamide › Sulfadiazine analogs: anti-Toxoplasma in vitro...
Recherchemedicale.com › Composés chimiques organiques › Composés du soufre › Sulfones › Sulfonamides › Sulfadiazine analogs: anti-Toxoplasma in vitro...
Recherchemedicale.com › Composés hétérocycliques › Composés hétéromonocycliques › Azoles › Triazoles › Sulfadiazine analogs: anti-Toxoplasma in vitro...